Tech Company Financing Transactions
Granite Bio Funding Round
Granite Bio closed a $100 million venture capital round on 4/24/2025. Backers included Versant Ventures, Forbion Capital Partners and Novartis Venture Fund.
Transaction Overview
Company Name
Announced On
4/24/2025
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to expand operations and its R&D efforts.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Aeschenvorstadt 36
Basel, 4051
CH
Basel, 4051
CH
Phone
Website
Email Address
Overview
Granite Bio AG is a privately held biotech company founded in 2021 and based in Basel, Switzerland. The company specializes in developing first-in-class therapeutic antibodies targeting the fundamental biology of inflammation, autoimmunity, and fibrosis. Their lead candidates, GRT-001 and GRT-002, are designed to selectively deplete pathogenic cells, offering novel treatment approaches for chronic inflammatory and fibrotic diseases. ?
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Patrick Loustau
Chief Medical Officer
Dominik Hartl
Chief Scientific Officer
Gijs Brink
Browse more venture capital transactions:
Prev: 4/24/2025: World Class Health venture capital transaction
Next: 4/24/2025: Channel Factory venture capital transaction
Share this article
About Database of VC Transactions
We record tech company VC transactions. All VC database entries reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs